



INVESTORS PRESENTATION

TSX-V: **NU** | OTCQB: **NRXCF** | FRA: **1N9**

26TH APRIL, 2021

DISCLAIMER

Certain information contained in this presentation constitutes “forward-looking information” and “forward-looking statements” (referred to as the “forward looking statements”), which is information regarding possible events, conditions or results of operations that is based upon assumptions about future economic conditions and courses of action. All information other than statements of historical fact may be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “seek”, “expect”, “anticipate”, “budget”, “plan”, “estimate”, “continue”, “forecast”, “intend”, “believe”, “predict”, “potential”, “target”, “may”, “could”, “would”, “might”, “will”, and similar words or phrases (including negative variations) suggesting future outcomes or statements regarding an outlook. NeutriSci International Inc. (the “Corporation”) has based these forward-looking statements on its current expectations and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of significant uncertainties inherent in the forward-looking statements included in this presentation, the inclusion of such information should not be regarded as a representation by the Corporation or any other person that the Corporation’s objectives or plans will be achieved. Forward-looking statements in this presentation include, but are not limited to, statements relating to: the Corporation’s expectations regarding its revenue and operations; the Corporation’s plans for and timing of expansion of its products and services; the Corporation’s future growth plans; the Corporation’s ability to attract new clients and develop and maintain existing relationships; the Corporation’s ability to attract and retain personnel; the Corporation’s competitive position and its expectations regarding competition; regulatory developments and the regulatory environments in which the Corporation operates; and anticipated trends and challenges in the Corporation’s business and the markets in which it operates.

Forward-looking statements are based on certain material assumptions and analysis made by the Corporation, and the opinions and estimates of management as of the date such statements are made and they represent management’s best judgment based on facts and assumptions that management considers reasonable in light of its experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties. The material assumptions upon which such forward-looking statements are based include, among others, assumptions with respect to: growth plans; the continuation of demand for the products and services of the Corporation’s business; the ability of the Corporation to access financing from time to time on favourable terms, a stable market and general economic conditions; the ability of the Corporation to protect its intellectual property rights; the Corporation’s ability to retain clients and existing relationships; and the continuation of executive and operating management, or the non-disruptive replacement of them on competitive terms. The Corporation makes no representation that reasonable business people in possession of the same information would reach the same conclusions. Although the Corporation believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect and the Corporation cannot assure that actual results will be consistent with these forward-looking statements. Given these risks, uncertainties and assumptions, investors should not place undue reliance on these forward-looking statements. Whether actual results, performance or achievements will conform to the Corporation’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, which discussed or referred to preliminary prospectus that accompanies this presentation.

These risks, uncertainties, assumptions and other factors could cause the Corporation’s actual results, performance, achievements and experience to differ materially from the Corporation’s expectations, future results, performances or achievements expressed or implied by the forward-looking statements. If the forward-looking statements prove to be incorrect, actual results might vary materially from those anticipated in those forward-looking statements. You are cautioned that the above list of risks, uncertainties, assumptions and other factors is not exhaustive, and there may be other factors that the Corporation has not identified.

The forward-looking statements made in this presentation relate only to events or information as of the date on which the statements are made in this presentation, and accordingly are subject to change after such dates. Except as required by law, the Corporation undertakes no obligation to update or revise any forward-looking statements included in this presentation, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of future events.

NeutriSci International Inc. reserves all rights in and to this presentation.



TABLE OF CONTENTS

2 **Disclaimer**

3 **Table of Contents**

4 **Overview/Investment Highlights**

5 **Technology**

9 **Facility**

12 **Management**

13 **Board of Directors**

14 **B2B & Contract Manufacturing Services**

15 **Product Samples**

16 **Current & Future Developments**

17 **Investment Highlights**

18 **Contacts**



OVERVIEW / INVESTMENT HIGHLIGHTS

NeutriSci International specializes in the development, formulation, and production of unique products for the Nutraceutical and CBD/THC industry . Our proprietary IP and technology creates a fast and efficient way to get ingredients directly into the bloodstream. Implementing our Technology has achieved industry setting standards, 94% bilingual absorption for Nutraceuticals, 116% for CBD and 131% for THC. Neutrisci's state of the art formulation and manufacturing facility focuses on B2B services and contract manufacturing services.

INVESTMENT HIGHLIGHTS

- Industry disrupting patent pending technology for CBD, THC, Nutraceutical and Pharmaceutical industry.
- First mover advantage: First publicly traded Canadian company to produce a range of CBD products for the Japanese market.
- High margin business, own manufacturing process with state-of-the-art in-house manufacturing facility.
- New Product Pipeline: Currently developing and formulating several new products for CBD, THC, Nutraceutical and Pharmaceutical industry.
- Owns numerous trademarks, industry disrupting patent and patent pending ingredients, technology and IP.
- Has agreements and MOU's in place with B2B partners around the world.

FUNDAMENTAL DATA (CAD)

SHARE STRUCTURE - TSX-V	NU
Shares Outstanding	149.9 million
Shares Fully Diluted	174.5 million
Share Price (CAD)	\$0.19
Market Cap	\$27.7 million
Year High	\$0.35
Year Low	\$0.035




TECHNOLOGY

NeutriSci's proprietary IP and technology creates a fast and efficient way to get ingredients into the body's bloodstream. Working with its B2B partners, the Company provides the expertise to develop, formulate, and create new products using novel ingredients combined with science and natural products.

The Company's IP and technology can be applied to many different categories in the beverage, food and nutraceutical space. NeutriSci's ingredients, technology and IP have demonstrated the ability to increase the absorption of ingredients into the body's blood stream. The result creates a safe and effective product for the consumer.

Click on the image below to watch how our technology works.



Our technology is setting industry benchmarks



CHALLENGE OF THE CBD/THC INDUSTRY



SLOW ABSORPTION



5% - 20% EFFECTIVE

DISADVANTAGES

- Only 5% - 20% bio-available when ingested
- On-set usually takes between 90 - 120 minutes
- Largely destroyed by stomach acid
- Bad taste upon oral intake
- Unable to significantly cross intestinal wall or blood-brain barrier
- Broken down by the liver, losing efficacy



FAST ABSORPTION





VERY EFFECTIVE
HARMFUL



FAST ABSORPTION



VERY EFFECTIVE



THE INDUSTRY DILEMMA


- Increasing CBD/THC bioavailability

CBD and THC Oil molecules have **low bioavailability** and are inherently **difficult to absorb**.

The competitive advantage begins with **increasing the bioavailability** of these molecules.



OUR INDUSTRY DISRUPTING SOLUTION



OUR COMPETITIVE ADVANTAGE



BUCCAL & SUBLINGUAL ABSORPTION

Buccal & Sublingual administration is a topical route of administration by which drugs held or applied in the buccal area (in the cheek) diffuse through the oral mucosa (tissues which line the mouth) and enter directly into the bloodstream.

The patented proprietary Neutrisci processes dramatically enhances sublingual absorption thus lowering response times in the body by bypassing hepatic metabolism.

NEUTRISCI TECHNOLOGY ENABLES:


- On-set in as little as **12 minutes**
- **94% Pterostilbene Sublingual absorption**
- Flavor masking for poor tasting compounds
- **6 – 7x more efficient** than ingestible edibles such as THC/CBD
- Less active ingredients needed to achieve desired results
- **116% CBD and 131%THC Sublingual absorption**

FACILITY

Our state-of-the-art facilities are equipped with the latest technologies, the most up-to-date resources, and the ability to scale up operations as needed. The multi-use facilities are in geographic locations which delivers the optimal environment to ship products anywhere in the world. This provides us with significant cost saving measures which ultimately lead to higher margins and greater revenues. Our Las Vegas Facility is our crown jewel, as it contains or patent pending Cryolization equipment, enabling us to implement our patent pending technology with new products.



NEW



Locations

- Primary Facility – 8,000 Sq. Feet
- Ancillary Facilities – 12,000 Sq. Feet
- Located: Nevada, Washington, & Florida

Equipment

- 15 Production Machines
- Mixers, Grinders, Heat Sealing Tunnel
- Full R&D laboratory
- Beverage, Food, & Nutraceutical Packaging Equipment

Capacity Output

- 648 kg/day minimum
- 540,000 tablets/day
- 195,000 sachets/day

LABORATORY



GRINDING &
POWDER PREP



PRODUCTION ROOM



QUALITY CONTROL &
FINAL PACKING



MANAGEMENT

GLEN REHMAN CEO & DIRECTOR

- With NeutriSci since January 2010
- Over 20 years of business practice of which includes Banking, Retail, Operations and Management
- Former Senior Manager of Operations of Bernard Callebaut Chocolates and was responsible for domestic and international expansion operations
- Former COO for Vauntcom Media

ROBERT CHISHOLM CFO

- Former CFO with PNI Digital Media Inc. (formerly PhotoChannel Networks Inc.)
- CFO of Emprise Capital Corp.
- 25 years of public market experience in finance and administration
- Director and senior officer in finance and administration
- Director and senior officer of a number of TSX listed companies

JAYCEE WATERS LOGISTICS & OPERATIONS MANAGER

- 12 years experience with operations, transportation and product procurement.
- Logistics Manager for DHL Western Canada
- 2015 DHL Employee of the Year



BOARD OF DIRECTORS

JEFF DURNO **DIRECTOR & CHAIRMAN**

- Partner of Cassels Brock and Blackwell LLP
- Chairman of Emprise Capital Corp., a Vancouver based merchant banking company
- 20+ years public market experience
- Served as a Director and Senior Officer of numerous TSX listed companies
- Called to the Bar of Ontario in 1993 and British Columbia in 1994 and is a member of the Law Society of Upper Canada

DANA MONTENEGRO **DIRECTOR**

- 18+ years experience in global innovation management, marketing, design driven change and applied creativity
- Former Driver of Culture, innovation & inspiration for Red Bull Energy Drink GmbH
- Lead change and innovation initiatives in Latin America and Europe
- Co-founder of Seriously Creative, an innovation, design thinking and creative problem solving consultancy
- Co-founder of green technology start-up, Grasslark.

ANTHONY HUGENS **DIRECTOR**

- Former Strategic Planning Manager at Walmart for over 13 years
- Former Director of Retail Development at CMS Famous Toys Ltd.
- Former Director of eCommerce for The Brick

GLEN REHMAN **PRESIDENT & DIRECTOR**

- With NeutriSci since January 2010
- Over 20 years of business practice of which includes Banking, Retail, Operations and Management
- Former Senior Director of Operations of Bernard Callebaut Chocolates and was responsible for domestic and international expansion operations
- Former COO for Vauntcom Media



B2B & CONTRACT MANUFACTURING SERVICES



Contract Manufacturing Services

- White Label
- Private Label
- Co-Branding



PRODUCT SAMPLES

BEVERAGE/THC



POWDER/THC



THC



NUTRACEUTICAL

TABLETS

CBD



CURRENT & FUTURE DEVELOPMENTS


CBD / THC / Hemp Industry

Implementing patent pending Cryolization technology within the industry, establishing our technology as the gold standard. Strong focus on CBD/THC drink & beverage industry taking advantage of our leading water soluble technology.



Pharmaceutical Industry

Establishing new B2B pharmaceutical division with the focus to implement our technology with pharmaceutical companies which are seeking to increase the efficacy and response time of their existing medications in the human body.



Nutraceutical Industry

Strong focus on improving the effectiveness of existing nutraceutical products in the industry. NeutriSci is currently formulating & developing several new products for the dietary supplement sector.




INVESTMENT HIGHLIGHTS

INVESTMENT HIGHLIGHTS

- Industry disrupting patent pending technology for CBD, THC, Nutraceutical and Pharmaceutical industry.
- First mover advantage: First publicly traded Canadian company to produce a range of CBD products for the Japanese market.
- High margin business, own manufacturing process with state-of-the-art in-house manufacturing facility.
- New Product Pipeline: Currently developing and formulating several new products for CBD, THC, Nutraceutical and Pharmaceutical industry.
- Owns numerous trademarks, industry disrupting patent and patent pending ingredients, technology and IP.
- Has agreements and MOU's in place with B2B partners around the world.

FUNDAMENTAL DATA (CAD)

SHARE STRUCTURE - TSX-V	NU
Shares Outstanding	149.9 million
Shares Fully Diluted	174.5 million
Share Price (CAD)	\$0.19
Market Cap	\$27.7 million
Year High	\$0.35
Year Low	\$0.035



CONTACTS

INVESTOR RELATIONS

NeutriSci International Inc.

Direct: (403) 264-6320

Fax: (403) 252-2106

Email: investors@neutrisci.com

CORPORATE HEADQUARTERS

1600 - 609 Granville St
Vancouver, B.C. V7Y 1C3
Canada